Loading…
← CockpitCompetitor Analysis › DIA.MI DiaSorin S.p.A.Open in the cockpit ↗

DiaSorin S.p.A.DIA.MICompetitor analysis, valuation and peers

Italy · EUR·Health Care›Medical Specialties

Italian in-vitro diagnostics maker of immunodiagnostic and molecular test kits and analyzers for infectious disease and other conditions.

≈ A mid-cap diagnostics maker like Quidel OrthoMomentum leader 85
Mkt cap
$4.81B
US dollars, full cap
Free float
39%
of shares outstanding
$/day
$12.4M
20-day average traded
Fwd P/E
20.5×
forward earnings
ROIC−WACC
+2.7 pp
WACC 6.2%
Hurdle
-2 pp
Req g minus delivered
Next earnings
114 days
12 Mar 2027
Close · EUR€81.22
1D-0.8%
1W-1.7%
1M+2.2%
3M+8.1%
6M+23.9%
YTD+18.4%
1Y+37.7%
ATR %2.4%
52w lowhigh5.4% off high

What DiaSorin does

Italian in-vitro diagnostics maker of immunodiagnostic and molecular test kits and analyzers for infectious disease and other conditions.

Places analyzers in laboratories, often on loan or lease, and earns from the test kits the analyzers consume, so each installed machine produces repeat revenue; the more tests offered on one analyzer, the more reason a lab has to stay. The 2021 purchase of Luminex added a molecular-testing platform.

In one line: A mid-cap diagnostics maker like Quidel Ortho.

Products and services

  • Immunodiagnostics (LIAISON)
  • Molecular diagnostics (PCR)
  • Licensed technologies
  • Life sciences testing

Customers

  • Hospital labs
  • Reference labs
  • Blood banks

Where it sits in the supply chain

  • Healthcare diagnostics
  • In-vitro diagnostics
  • Immunoassay & molecular testing

What could go right

  • Infectious disease testing demand
  • Menu expansion into new assays

What could go wrong

  • Reimbursement pressure on lab testing
  • Post-COVID testing volume normalization

Moat: narrow (installed base, switching costs, IP / patents). Closed-system analyzers lock customers into DiaSorin's proprietary reagents once installed.

Headquarters: Saluggia, Italy · Founded: 1968 · Employees: 3,272

Named competitors

DiaSorin at a glance

Size DiaSorin (DIA.MI) is an Italy Health Care company (Medical Specialties) with a market value of $4.81B, the 45th largest of 121 Italy companies the cockpit tracks. Shares closed at €81.22 on 18 Nov 2026.

Performance Over six months the shares gained 23.9%, against +22.8% for the median peer and +3.1% for the Italy market (cap-weighted) — 10th highest of 21 in its peer set.

Growth Revenue fell 3.1% over the last twelve months (peer median +8.1%); the operating margin is 23.6% (peer median 13.6%).

Valuation It trades at 20.5× forward earnings against a peer median of 20.0× (9th most expensive of 20).

Price implies For today's price to make sense, revenue must grow about 4% a year for seven years (Req g). Recent delivered growth is +6%, so the hurdle is -2 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 2.7 points above its cost of capital (6.2% WACC).

Next results Next results expected around 12 Mar 2027 (exchange calendar; dates can move).

Relative performance

10011012013021 May 202621 Aug 202618 Nov 2026Peer median 126DIA.MI 124
Six months, rebased to 100: DiaSorin against the median of its 20 peers (local-currency closes).

DiaSorin financials

Reported figures in EUR; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue€1.18B€1.20B€1.19B€1.15B€1.36B
Revenue growth—+1%+3%-16%—
Gross profit€683M€700M€708M€669M€827M
EBITDA€405M€433M€407M€351M€502M
Net income€141M€156M€188M€160M€241M
Free cash flow€238M€281M€307M€266M€336M
Capital expenditure€130M€138M€120M€113M€114M
Total debtn/a€791M€1.01B€1.19B€1.35B

Quarterly statements and history in the cockpit →

DiaSorin competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+50%+100%-20%0%+20%300677MMEDSHCGRALMMSIICUILIVNSTVN002223HAEFIECDNA002432688617NVST1SXP603014TECNTFX4203DIA.MI6-month return →1-month return →
Up and to the right = strong over both horizons. DiaSorin is the large dot.

Fundamentals: revenue growth against valuation

-20%0%+20%+40%20×40×300677MMEDSHCMMSIICUILIVNSTVN002223HAEFIECDNA002432688617NVST1SXPTECNTFX4203DIA.MIRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. DiaSorin is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%0%20%40%300677SHCMMSIICUI002223HAEFIE002432688617NVSTTECNTFX4203DIA.MIGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. DiaSorin is the large dot.

DiaSorin competitors and peer comparison

Head to head with its named competitors (DIA.MI vs ABT vs SHL.DE vs BIM.PA)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
DiaSorin DIA.MI$4.81B+24%-3%24%20.5×4.1%
Abbott Laboratories ABT$181B+18%+10%14%17.9×16.5%
Siemens Healthineers SHL.DE$53.7B+27%+1%14%18.9×9.6%
bioMerieux BIM.PA$11.8B+26%-3%15%20.2×8.6%

How DiaSorin compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

DiaSorin against its 20 peers (data as of 18 Nov 2026)
MeasureDIA.MIPeer medianRank in peer set
1-month return+2.2%+5.5%9th lowest of 21
6-month return+23.9%+22.8%10th highest of 21
Distance from 52-week high-5.4%-18.0%4th highest of 21
Revenue growth (TTM)-3.1%+8.1%5th lowest of 21
Operating margin23.6%13.6%3rd highest of 20
Forward P/E20.5×20.0×9th most expensive of 20
Growth the price implies (Req g, 7 yrs)4.1%10.9%5th least demanding of 18
Growth delivered (Del g)+6.3%+8.2%6th lowest of 18
Hurdle (Req g minus delivered)-2.2 pp+1.6 pp5th least demanding of 18
ROIC minus cost of capital+2.7 pp+1.1 pp8th highest of 20
EV / EBITDA12.9×13.8×7th cheapest of 14
Net debt / EBITDA2.1×0.9×5th most indebted of 15

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
DiaSorin DIA.MIItaly$4.81B+24%-3%24%20.5×4.1%+6.3%
Intco Medical Technology 300677.SZChina$4.82B-2%+33%20%18.5×-3.5%-6.4%
MiniMed MMEDUnited States$4.78B+46%+14%14%26.3×n/an/a
Sotera Health SHCUnited States$4.65B+5%+7%37%15.7×14.4%+7.3%
GRAIL GRALUnited States$4.59B+67%+17%-332%n/an/an/a
Merit Medical Systems MMSIUnited States$5.15B+33%+9%14%19.1×12.6%+9.5%
ICU Medical ICUIUnited States$4.46B+38%-6%8%19.4×18.9%+11.9%
LivaNova LIVNUnited States$5.21B+28%+12%15%20.9×14.2%+8.2%
Stevanato STVNUnited States$4.19B-13%+12%18%22.5×13.1%+12.1%
Jiangsu Yuyue Medical Equipment & Supply 002223.SZChina$4.18B-3%-1%13%20.0×4.9%+3.4%
Haemonetics HAEUnited States$5.59B+106%+4%19%20.7×10.9%+8.9%
Fielmann FIE.DEGermany$3.92B-3%+3%14%17.1×-5.5%+11.3%
CareDx CDNAUnited States$3.91B+252%+39%1%50.6×n/an/a
Andon Health 002432.SZChina$3.86B-24%-30%-26%16.1×-6.6%-7.4%
APT Medical 688617.SSChina$6.06B+23%+28%37%38.6×9.0%+40.1%
Envista NVSTUnited States$3.81B0%+10%12%14.7×4.8%+7.1%
SCHOTT Pharma AG & Co. KGaA 1SXP.DEGermany$3.73B+32%+4%15%23.0×12.7%+11.0%
Shandong Weigao Blood Purification Products 603014.SSChina$3.63B-1%+4%n/a20.4×-1.2%+8.1%
Tecan TECN.SWSwitzerland$3.60B+59%-4%1%35.5×45.4%+3.8%
Teleflex TFXUnited States$6.58B+23%-29%12%16.7×16.5%-4.7%
Sumitomo Bakelite 4203.TJapan$3.50B+7%+15%13%15.9×8.6%+8.9%

Questions

Who are DiaSorin's main competitors?
Named competitors: Roche Diagnostics (private or unlisted), Abbott Laboratories (ABT), Siemens Healthineers (SHL.DE), bioMerieux (BIM.PA), Hologic (private or unlisted). The cockpit's measured peer set (industry) also includes Intco Medical Technology (300677.SZ), MiniMed (MMED), Sotera Health (SHC), GRAIL (GRAL), Merit Medical Systems (MMSI), ICU Medical (ICUI).
Is DiaSorin expensive compared with its peers?
On forward p/e it trades at 20.5× against a peer median of 20.0×, 9th most expensive of 20 in its peer set. For today's price to make sense, revenue must grow about 4% a year for seven years (Req g). Recent delivered growth is +6%, so the hurdle is -2 pp: the price already allows for a slowdown.
How has DiaSorin stock performed?
Over six months to 18 Nov 2026 the shares returned +23.9% against +22.8% for the median peer; over one year +37.7%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.